Cell2Cure
  • Home
  • The Company
  • Research, Technology and IP
  • Clinical
  • Investor and Partners
  • Publications
  • News
  • Contact us
Select Page

Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)

by Backoffice | Feb 9, 2023 | Studies and testing

The first patient with diabetic foot ulcer was treated with Cell2Cure’s allogeneic adipose tissue-derived mesenchymal stromal cell product (C2C_ASCs) January 24, 2023 at Bispebjerg University Hospital, Copenhagen, Denmark. The STEMFOOT study is carried out in...

Recent Posts

  • Cell2Cure researched by Tech Journal »Ingeniøren«
  • Enrolment finalized in the lung transplantation ASC phase I-II clinical trial
  • Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)
  • The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome
  • Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome

Recent Comments

    Archives

    • May 2023
    • April 2023
    • February 2023
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • July 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • January 2020

    Categories

    • Collaborations
    • Patents
    • Studies and testing
    • Trial results

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2021 Cell2Cure | CVR.no 39401975 | Designed by ICR-Design ApS